TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28916992

Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 (400 IU)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 (1000 IU)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 25982649

Group type: EXPERIMENTAL
Intervention: XPF 0.3 mm caps
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: XPF 0.5 mm caps
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard fabric caps
Number of subjects: 197
Study: 23664161

Group type: EXPERIMENTAL
Intervention: MiroCam (MC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: PillCam (PC)
Number of subjects: 105
Study: 21935794

Group type: EXPERIMENTAL
Intervention: Ischemia group (laparotomy and tying of the superior mesenteric artery)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham group (laparotomy without ischemia)
Number of subjects: 21
Study: 19646048

Group type: EXPERIMENTAL
Intervention: Nutritionally enhanced beans (NEB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritionally enhanced maize (NEM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional beans (CB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional maize (CM)
Number of subjects: 0
Study: 17493496

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive fluid resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective vasoconstrictors
Number of subjects: 0
Study: 15505276

Group type: COMPARATOR
Intervention: TAM 30 mg/d for 3 years
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: EPI 30 mg on days 1, 8, and 15 every 28 days for six cycles plus TAM 30 mg/d for 3 years
Number of subjects: 338
Study: 11737422

Group type: EXPERIMENTAL
Intervention: Brief dynamic psychotherapy for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study: 9559107

Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure (mean concentration of 2.37 ppm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (10 students without FA exposure)
Number of subjects: 13
Study: 8145901

Group type: EXPERIMENTAL
Intervention: Intensive physical rehabilitation program for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal physical activity for 4 weeks
Number of subjects: 0
Study: 3481276

Group type: EXPERIMENTAL
Intervention: Protective supporting appliance during intubation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prolonged orotracheal intubation without protective appliance
Number of subjects: 30
Study: 29792232

Group type: EXPERIMENTAL
Intervention: CI-guided goal-directed hemodynamic therapy (GDHT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study: 27271724

Group type: EXPERIMENTAL
Intervention: Radical debridement, bone graft, and instrumentation (Group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Isolated posterior instrumentation without debridement (Group B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Radical debridement (Group A)
Number of subjects: 74
Study: 25285430

Group type: EXPERIMENTAL
Intervention: Hedonic story
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eudaimonic story
Number of subjects: 0
Study: 21938436

Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep in mild OSA patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep in moderate to severe OSA patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Complete denture wear during sleep in mild OSA patients (supine position)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Preference for sleeping with upper and lower dentures
Number of subjects: 23
Study: 15735202

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment for 10 days (T(2)D+); plasma glucose 5.5 ± 0.2 mmol/l
Number of subjects: 8

Group type: COMPARATOR
Intervention: Withdrawal of all antidiabetic medications for 2 weeks (T(2)D-); plasma glucose 12.6 ± 1.0 mmol/l
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (weight-matched and lean nondiabetic subjects)
Number of subjects: 8
Study: 11895895

Group type: EXPERIMENTAL
Intervention: BCL-2 antisense oligonucleotide (G3139) at 6.9 mg/kg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BCL-2 antisense oligonucleotide (G3139)
Number of subjects: 35
Study: 10332543

Group type: EXPERIMENTAL
Intervention: Intravenous salmon calcitonin 200 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term studies using intranasal calcitonin
Number of subjects: 0
Study: 7676060

Group type: EXPERIMENTAL
Intervention: HAV infection
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: HBV infection
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: HCV infection
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: EBV infection
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: HCV infection (attributed cases)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Parenteral spread of infections agents
Number of subjects: 224
Study: 2202902

Group type: EXPERIMENTAL
Intervention: Isotretinoin (50 to 100 mg per square meter of body-surface area per day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 6117260

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin administered 12 hours before operation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31736382

Group type: EXPERIMENTAL
Intervention: Chefs in Action program (3 cooking workshops)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Single cooking workshop (comparison group 1, n=16)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Single cooking workshop (comparison group 3, n=24)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Single cooking workshop (comparison group 2, n=36)
Number of subjects: 25
Study: 30959146

Group type: EXPERIMENTAL
Intervention: Adjusted medication protocol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fixed medication protocol
Number of subjects: 42
Study: 28381416

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg/day for 21 days of a 28-day cycle)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Investigator's Choice (IC) including gemcitabine, rituximab, etoposide, or oxaliplatin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 102

Group type: COMPARATOR
Intervention: Investigator's Choice (IC)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lenalidomide (non-GCB subtype)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Investigator's Choice (IC) (non-GCB subtype)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lenalidomide (GCB subtype)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Investigator's Choice (IC) (GCB subtype)
Number of subjects: 102
Study: 25151065

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 223

Group type: COMPARATOR
Intervention: Group therapy
Number of subjects: 223
Study: 23842846

Group type: EXPERIMENTAL
Intervention: Amplatzer
Number of subjects: 660

Group type: COMPARATOR
Intervention: CardioSEAL-STARflex
Number of subjects: 660

Group type: COMPARATOR
Intervention: Helex
Number of subjects: 660
Study: 21459902

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18652322

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rehabilitation therapy
Number of subjects: 120
Study: 16875928

Group type: EXPERIMENTAL
Intervention: Fosinopril (low dosage)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fosinopril (high dosage)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fosinopril (low, medium, high dosages)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 12629054

Group type: EXPERIMENTAL
Intervention: Fluconazole (Fluzole 100 mg/day) starting from the sixth irradiation session throughout the treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group without specific prophylaxis (fluconazole only when mycotic infections appeared)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluconazole group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluconazole (Fluzole 100 mg/day)
Number of subjects: 80
Study: 11111968

Group type: EXPERIMENTAL
Intervention: Withdrawal of cyclosporine and replacement with anti-thymocyte globulin (ATG)
Number of subjects: 0
Study: 9311220

Group type: EXPERIMENTAL
Intervention: Intravenous neostigmine (2 ml, 1 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (2 ml of 0.9% saline)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Atropine (1 ml, 0.5 mg) and neostigmine (2 ml, 1 mg)
Number of subjects: 75
Study: 8225701

Group type: EXPERIMENTAL
Intervention: Seaprose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3760520

Group type: EXPERIMENTAL
Intervention: Cholecystectomy and appendectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cholecystectomy alone
Number of subjects: 120
Study: 29482648

Group type: EXPERIMENTAL
Intervention: high support career guidance intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: service as usual
Number of subjects: 140
Study: 27077358

Group type: EXPERIMENTAL
Intervention: App variants with active contagion strategies and increased duration of use
Number of subjects: 9042

Group type: COMPARATOR
Intervention: App variants without active contagion strategies
Number of subjects: 9042
Study: 24211309

Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 707

Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 707
Study: 23011423

Group type: EXPERIMENTAL
Intervention: Microcurrent reflexology sessions and cortexin treatment (10 mg, 10 injections)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reflexology treatments only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microcurrent reflexology with cortexin
Number of subjects: 60
Study: 19897055

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 18632186

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 625
Study: 15737667

Group type: EXPERIMENTAL
Intervention: Tryptophan-free mixture (31.2 g of amino acids)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control mixture (33.2 g of amino acids)
Number of subjects: 48
Study: 14523211

Group type: EXPERIMENTAL
Intervention: Salicylic sugar powder
Number of subjects: 244

Group type: COMPARATOR
Intervention: Chlorhexidine (4% detergent water solution)
Number of subjects: 244
Study: 10880033

Group type: EXPERIMENTAL
Intervention: Complete intervention group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Partial intervention group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Minimal intervention group
Number of subjects: 144
Study: 8895639

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 262

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 262
Study: 2071262

Group type: EXPERIMENTAL
Intervention: 300 mg theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg theophylline followed by 400 mg rufloxacin after 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine followed by 400 mg rufloxacin after 30 min
Number of subjects: 12
Study: 6357692

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Bay K 9320) 20 mg, three times daily for three weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Bay K 9320)
Number of subjects: 24
Study: 31995024

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg for three months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy subgroup with Esomeprazole
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no esomeprazole)
Number of subjects: 32
Study: 30744298

Group type: EXPERIMENTAL
Intervention: Community-based diabetes self-management intervention for 3 months
Number of subjects: 500
Study: 28577505

Group type: EXPERIMENTAL
Intervention: UP+TAU
Number of subjects: 29

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 29
Study: 25725426

Group type: EXPERIMENTAL
Intervention: High saturated fat meal
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil meal
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Loneliness assessment
Number of subjects: 42
Study: 24429918

Group type: EXPERIMENTAL
Intervention: Neurocognitive therapeutic exercise
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional therapeutic exercise
Number of subjects: 48
Study: 22230918

Group type: EXPERIMENTAL
Intervention: 29-h total sleep deprivation (TSD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (normal night)
Number of subjects: 10
Study: 19669019

Group type: EXPERIMENTAL
Intervention: Maternal inspired fraction of oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Supplementary oxygen administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maternal hyperoxia
Number of subjects: 20
Study: 17438407

Group type: EXPERIMENTAL
Intervention: Sarpogrelate hydrochloride 100 mg 3 times per day orally for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 21
Study: 15455745

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Barrier membranes (control)
Number of subjects: 45
Study: 11181869

Group type: EXPERIMENTAL
Intervention: GKI infusion (500 ml 10% glucose, 20 mmol potassium chloride, 16 units of insulin)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control therapy with 154 mmol/l (0.9%) saline at 100 ml/h for 24 hours
Number of subjects: 145
Study: 10211539

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400 mg loading dose on day 1, followed by 200 mg daily for 9 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 24
Study: 7752669

Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term physical exercise at a sufficiently intense level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0
Study: 2620532

Group type: EXPERIMENTAL
Intervention: Cervagem (1 mg vaginal suppository for 4 hours)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dilapan (osmotic dilator intracervically for 4 hours)
Number of subjects: 40
Study: 1247222

Group type: EXPERIMENTAL
Intervention: Vibration (41.0 +/- 5.4 Hz; 2 mm amplitude) applied to the back for one hour
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 10
Study: 31764462

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal Sleep
Number of subjects: 10
Study: 29605624

Group type: EXPERIMENTAL
Intervention: Tiotropium-olodaterol 5 μg-5 μg once daily
Number of subjects: 7880

Group type: COMPARATOR
Intervention: Tiotropium 5 μg once daily
Number of subjects: 7880

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 7880
Study: 26537308

Group type: EXPERIMENTAL
Intervention: Neuronavigated high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex, 20 sessions
Number of subjects: 5
Study: 24730708

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 22610452

Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline, nebulized twice daily for 48 weeks
Number of subjects: 321

Group type: COMPARATOR
Intervention: 0.9% isotonic saline, nebulized twice daily for 48 weeks
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline
Number of subjects: 321

Group type: COMPARATOR
Intervention: 0.9% isotonic saline
Number of subjects: 321
Study: 20415801

Group type: EXPERIMENTAL
Intervention: Xylitol rinse (20 mL of an aqueous solution of xylitol twice daily for 60 seconds, dose: 4.4 g/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Xylitol chewing gum (two xylitol gum pellets for at least 5 minutes three times daily, dose: 4.3g/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Negative control (used neither product)
Number of subjects: 105
Study: 18710748

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist therapy (2, 6-month cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thalidomide treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low baseline dihydroxytestosterone and age over 67 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior local radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low baseline dihydroxytestosterone and testosterone, low testosterone nadir, and white race
Number of subjects: 0
Study: 15933273

Group type: EXPERIMENTAL
Intervention: Person-environment (P-E) fit problems
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADLs) dependence
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Functional limitations and dependence on mobility devices
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Environmental barriers
Number of subjects: 72
Study: 11375230

Group type: EXPERIMENTAL
Intervention: Perineal massage during the second stage of labour with a water soluble lubricant
Number of subjects: 1340

Group type: COMPARATOR
Intervention: Control group (no perineal massage)
Number of subjects: 1340
Study: 11398305

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray 1 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray 0.5 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray (both doses)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray
Number of subjects: 52
Study: 7880598

Group type: EXPERIMENTAL
Intervention: Starting Again rehabilitation programme
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 199
Study: 2464912

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (200 mg per day for 4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 10
Study: 2186673

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 200 micrograms bid
Number of subjects: 99

Group type: COMPARATOR
Intervention: Matching placebo bid
Number of subjects: 99
Study: 236737

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication + parietal cell vagotomy (PCV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nissen fundoplication alone
Number of subjects: 29
Study: 31864178

Group type: EXPERIMENTAL
Intervention: Dabrafenib (BREAK-2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Dabrafenib (BREAK-3)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Dacarbazine (BREAK-3)
Number of subjects: 92
Study: 31659612

Group type: EXPERIMENTAL
Intervention: ALBI grade 2
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: ALBI grade 3
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Serum AFP ≥ 100 ng/ml
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Total tumor volume ≥ 250 cm3
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Ascites
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Performance status 0–1
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Vascular invasion or metastasis
Number of subjects: 2186
Study: 28496190

Group type: EXPERIMENTAL
Intervention: Combination budesonide/formoterol inhaler (single maintenance and reliever therapy)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Fixed dose budesonide/formoterol with salbutamol as reliever (Standard regimen)
Number of subjects: 303
Study: 25888520

Group type: EXPERIMENTAL
Intervention: Home-based tele-supervising rehabilitation
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 210
Study: 22825926

Group type: EXPERIMENTAL
Intervention: Focused Playtime Intervention (FPI)
Number of subjects: 70
Study: 20728307

Group type: EXPERIMENTAL
Intervention: 6 hours of voice training
Number of subjects: 65

Group type: COMPARATOR
Intervention: No voice training (Control)
Number of subjects: 65
Study: 19367246

Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) 3 times a week for 5 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no MLD)
Number of subjects: 20
Study: 17909141

Group type: EXPERIMENTAL
Intervention: Hygiene intervention from March 1, 1991, to May 31, 1992.
Number of subjects: 928

Group type: COMPARATOR
Intervention: Control group (no hygiene intervention).
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Hygiene intervention.
Number of subjects: 928
Study: 15531509

Group type: EXPERIMENTAL
Intervention: recombinant human (rh) IGF‐I (20 microg/kg sc)
Number of subjects: 17

Group type: COMPARATOR
Intervention: saline/rest, aerobic exercise, GHRH (1 microg/kg iv bolus), or GH‐releasing peptide‐2 (1 microg/kg iv bolus)
Number of subjects: 17
Study: 11797116

Group type: EXPERIMENTAL
Intervention: Ozonized autohemotransfusion
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-ozonized autohemotransfusion (control)
Number of subjects: 27
Study: 9797591

Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup (intervention group)
Number of subjects: 230